203 related articles for article (PubMed ID: 30755064)
1. Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway.
Ye G; Qin Y; Wang S; Pan D; Xu S; Wu C; Wang X; Wang J; Ye H; Shen H
Cancer Biol Ther; 2019; 20(5):711-719. PubMed ID: 30755064
[TBL] [Abstract][Full Text] [Related]
2. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
3. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
Wang Q; Lu D; Fan L; Li Y; Liu Y; Yu H; Wang H; Liu J; Sun G
Int J Mol Med; 2019 Jan; 43(1):475-488. PubMed ID: 30365092
[TBL] [Abstract][Full Text] [Related]
4. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
[TBL] [Abstract][Full Text] [Related]
5. miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.
Song L; Zhang W; Chang Z; Pan Y; Zong H; Fan Q; Wang L
Med Sci Monit; 2017 Apr; 23():1741-1750. PubMed ID: 28394882
[TBL] [Abstract][Full Text] [Related]
6. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.
Zhang X; Shao J; Li X; Cui L; Tan Z
Oncol Rep; 2019 Feb; 41(2):1067-1074. PubMed ID: 30483804
[TBL] [Abstract][Full Text] [Related]
9. AKT activation was not essential for hepatocellular carcinoma cell survival under glucose deprivation.
Zhou J; Tang Y; Xie ZJ; Lu JN; Deng JH; Huang XW; Chuan Hooi S; He M; Lu GD
Anticancer Drugs; 2017 Apr; 28(4):427-435. PubMed ID: 28085697
[TBL] [Abstract][Full Text] [Related]
10. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
12. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
Tian T; Nan KJ; Guo H; Wang WJ; Ruan ZP; Wang SH; Liang X; Lu CX
Oncol Rep; 2010 Jun; 23(6):1593-600. PubMed ID: 20428814
[TBL] [Abstract][Full Text] [Related]
13. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
14. MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Zhang Y; Zheng L; Ding Y; Li Q; Wang R; Liu T; Sun Q; Yang H; Peng S; Wang W; Chen L
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1132-1140. PubMed ID: 26031366
[TBL] [Abstract][Full Text] [Related]
15. Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Baba A; Shimizu M; Ohno T; Shirakami Y; Kubota M; Kochi T; Terakura D; Tsurumi H; Moriwaki H
BMC Cancer; 2013 Oct; 13():465. PubMed ID: 24103747
[TBL] [Abstract][Full Text] [Related]
16. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
Liu Y; Zhao Y; Guo L
Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
[TBL] [Abstract][Full Text] [Related]
17. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Zhao C; Wang B; Liu E; Zhang Z
Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
[TBL] [Abstract][Full Text] [Related]
18. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.
Nemazanyy I; Espeillac C; Pende M; Panasyuk G
Biochem Soc Trans; 2013 Aug; 41(4):917-22. PubMed ID: 23863156
[TBL] [Abstract][Full Text] [Related]
19. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.
Iansante V; Choy PM; Fung SW; Liu Y; Chai JG; Dyson J; Del Rio A; D'Santos C; Williams R; Chokshi S; Anders RA; Bubici C; Papa S
Nat Commun; 2015 Aug; 6():7882. PubMed ID: 26258887
[TBL] [Abstract][Full Text] [Related]
20. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
